Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.31 -0.31 (-1.16%)
Official Closing Price Updated: 7:00 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Which S&P500 stocks are the most active on Wednesday? ↗
Via Chartmill
News headline image
Rigel (RIGL) Q2 2026 Earnings Call Transcript ↗
VEPPANU launch and R289 data readouts drive second-half priorities. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗
This problem has a solution, and Pfizer is implementing it. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Arvinas (ARVN) Q2 2026 Earnings Call Transcript ↗
VEPPANU's FDA approval and $50 million Pfizer milestone fuel record net income. 
Via The Motley Fool
Topics Earnings
Most active S&P500 stocks in Monday's session ↗
Via Chartmill
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? ↗
Both of these stocks pay more than double the S&P 500 average of 1.1%. 
Via The Motley Fool
Topics Stocks
News headline image
BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer (PFE) Q2 2026 Earnings Call Transcript ↗
Non-COVID products surge 5% as Pfizer raises guidance and targets $9.7B in savings. 
Via The Motley Fool
Topics Earnings
Most active S&P500 stocks in Friday's session ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performanc... 
Via StockStory
Topics Earnings
News headline image
BridgeBio Pharma Q2 Earnings Call Highlights ↗
BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review... 
Via MarketBeat
Topics Earnings
News headline image
Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner? ↗
The stock's 6.4% yield is attractive, but it comes with risk. 
Via The Motley Fool
Pfizer (NYSE:PFE) Beats Q2 Expectations and Raises 2026 Revenue Guidance ↗
Via Chartmill
News headline image
Global Precision Medicine Market: Size, Trends, Drivers, and Forecast 2026-2033 ↗
The Precision Medicine industry is rapidly transforming healthcare delivery by enabling personalized treatment strategies tailored to genetic, environmenta 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
Berobenatide is one of the keys to Pfizer's future. 
Via The Motley Fool
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations
Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The comp... 
Via StockStory
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion.... 
Via StockStory
News headline image
3 Beaten-Down Stocks to Hold for the Next 10 Years ↗
Don't let their recent poor performances chase you away. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Q2 Earnings Call Highlights ↗
Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue... 
Via MarketBeat
Topics Earnings Intellectual Property
S&P 500 Prints Fresh Record As Chips Rip And Hormuz Talks Crack The Oil Trade ↗
Via Chartmill
Topics Stocks
News headline image
PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15... 
Via StockStory
Topics Artificial Intelligence
Looking for the most active stocks in the S&P500 index on Tuesday? ↗
Via Chartmill
News headline image
Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss ↗
Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways. 
Via Benzinga
News headline image
BioNTech Q2 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year... 
Via MarketBeat
Topics Earnings
News headline image
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings ↗
Dow rises 1.35% with technology sector leading market gains. Pfizer beats Q2 earnings expectations. Oil down 4.2%, gold up 0.8%, European markets higher. 
Via Benzinga
Topics Stocks
News headline image
Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat ↗
Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost. 
Via Investor's Business Daily
News headline image
Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15... 
Via StockStory
News headline image
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.